Fundraise & Transaction Update

AI SummaryClose X

Roquefort Therapeutics has successfully raised £300,000 to fund upfront costs related to a proposed transaction. This funding comprises £200,000 from advance subscription agreements with strategic investors and £100,000 from a loan provided by A2A Pharmaceuticals, Inc., accruing interest at 5%. The loan is repayable upon completion of the proposed transaction, 12 months from the loan date, or six months after termination of the transaction's term sheet; A2A Pharma has the option to convert the loan into ordinary shares at 2p per share. The Chairman participated in the advance subscriptions with an investment of £45,000.

Disclaimer*

UK 100

Latest directors dealings